Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension

• Status: Not yet recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The optimal antihypertensive treatment strategy in young and middle-aged hypertensive adults remains undefined. Clonidine controlled-release patches administered once a week might have the advantage of convenience. ECLIPSE trial is intended to observe the effect and patient tolerability of clonidine controlled-release patches (one patch per week for a total of 8 weeks) in the treatment of hypertension in young and middle-aged adults, compared with long-acting antihypertensive drug amlodipine. Clonidine patch was demonstrated ameliorating the early withdrawal symptoms during smoking cessation. This trial is also intended to observe its effect on smoking cessation in young and middle-aged male smokers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jing Liu
• Treatments: Amlodipine; Clonidine

Criteria

Inclusion Criteria:

1. 18-60 years old male with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg).

2. History of smoking and a desire to quit.

3. Signed informed consent form.

Exclusion Criteria:

1. Moderate or severe hypertension (systolic BP/diastolic BP >= 160/100 mmHg).

2. History of cardiopulmonary and vascular disease.

3. Severe liver or kidney disease.

4. Night shift workers, drivers, and those who work at height.